SUGAMMADEX Drug Patent Profile
✉ Email this page to a colleague
When do Sugammadex patents expire, and when can generic versions of Sugammadex launch?
Sugammadex is a drug marketed by Aspiro, B Braun Medical, and Zydus Pharms. and is included in three NDAs.
The generic ingredient in SUGAMMADEX is sugammadex sodium. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the sugammadex sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sugammadex
A generic version of SUGAMMADEX was approved as sugammadex sodium by ASPIRO on June 9th, 2023.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SUGAMMADEX?
- What are the global sales for SUGAMMADEX?
- What is Average Wholesale Price for SUGAMMADEX?
Summary for SUGAMMADEX
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| DailyMed Link: | SUGAMMADEX at DailyMed |
US Patents and Regulatory Information for SUGAMMADEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspiro | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214337-001 | Jun 9, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214290-001 | Oct 4, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aspiro | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214337-002 | Jun 9, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| B Braun Medical | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214279-001 | Aug 5, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214290-002 | Oct 4, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
